Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)

• The International Liver Cancer Association (ILCA) Annual
  Conference has selected the Can-Fite abstract for presentation
• Phase III trial for Namodenoson in advanced liver cancer is now
  under preparation
• Namodenoson has both Fast Track status and Orphan Drug
  designation from the U.S. FDA

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite
BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology
company with a pipeline of proprietary small molecule drugs that address
cancer, liver and inflammatory diseases, announced today that the
International Liver Cancer Association (ILCA) has accepted Can-Fite’s
abstract describing the latest data from the Company’s Phase II Liver
Cancer study of Namodenoson for an oral presentation at its annual
conference. The oral presentation titled “The Safety and Efficacy of
Namodenoson in the Second Line Treatment of Advanced Hepatocellular
Carcinoma (HCC) Patients with Underlying Child-Pugh B (CPB) Liver
Cirrhosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled” will
be delivered on September 22, 2019 during the Novel Targets and
Prognostic Markers Session from 11:00 am to 12:30 pm. The ILCA’s 13^th
Annual Conference will take place from September 20 to 22, 2019 in
Chicago, Illinois.

The ILCA
is the only international organization devoted exclusively to liver
cancer research for experts from all related disciplines. Its mission is
to lead a global community of physicians, scientists and allied
professionals through education and research with the goal to better
prevent and treat liver cancer.

“This is a very prestigious conference that brings together the leading
thought leaders, researchers, and physicians in the treatment of liver
cancer. Governing members of the ILCA thoroughly research each abstract
submission and select those that are most relevant to the advancement of
treating liver cancer. We are pleased that the selection committee sees
the potential of Namodenoson as a treatment for advanced liver cancer
patients with severe liver dysfunction. Based on both safety and
efficacy in this Phase II study, Can-Fite is preparing a Phase III
trial,” stated Can-Fite CEO Pnina Fishman.

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high
affinity and selectivity to the A3 adenosine receptor (A3AR).
Namodenoson is being evaluated as a second line treatment for
hepatocellular carcinoma, with a recently completed Phase II trial and
planned Phase III trial in this indication. The drug is currently in an
ongoing Phase II trial as a treatment for non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly
expressed in diseased cells whereas low expression is found in normal
cells. This differential effect accounts for the excellent safety
profile of the drug.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI) is an advanced
clinical stage drug development Company with a platform technology that
is designed to address multi-billion dollar markets in the treatment of
cancer, inflammatory disease and sexual dysfunction. The Company’s lead
drug candidate, Piclidenoson, is currently in Phase III trials for
rheumatoid arthritis and psoriasis. Can-Fite’s liver cancer drug,
Namodenoson, recently completed a Phase II trial for hepatocellular
carcinoma (HCC), the most common form of liver cancer, and is in a Phase
II trial for the treatment of non-alcoholic steatohepatitis (NASH).
Namodenoson has been granted Orphan Drug Designation in the U.S. and
Europe and Fast Track Designation as a second line treatment for HCC by
the U.S. Food and Drug Administration. Namodenoson has also shown proof
of concept to potentially treat other cancers including colon, prostate,
and melanoma. CF602, the Company’s third drug candidate, has shown
efficacy in the treatment of erectile dysfunction in preclinical studies
and the Company is investigating additional compounds, targeting A3AR,
for the treatment of sexual dysfunction. These drugs have an excellent
safety profile with experience in over 1,000 patients in clinical
studies to date. For more information please visit: www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among other
things, market risks and uncertainties, its product development efforts,
business, financial condition, results of operations, strategies or
prospects. In addition, from time to time, Can-Fite or its
representatives have made or may make forward-looking statements, orally
or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as “believe,” “expect,” “intend,” “plan,”
“may,” “should” or “anticipate” or their negatives or other variations
of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters.
These forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or with
the approval of one of Can-Fite’s authorized executive officers.
Forward-looking statements relate to anticipated or expected events,
activities, trends or results as of the date they are made. Because
forward-looking statements relate to matters that have not yet occurred,
these statements are inherently subject to risks and uncertainties that
could cause Can-Fite’s actual results to differ materially from any
future results expressed or implied by the forward-looking statements.
Many factors could cause Can-Fite’s actual activities or results to
differ materially from the activities and results anticipated in such
forward-looking statements. Factors that could cause our actual results
to differ materially from those expressed or implied in such
forward-looking statements include, but are not limited to: our history
of losses and needs for additional capital to fund our operations and
our inability to obtain additional capital on acceptable terms, or at
all; uncertainties of cash flows and inability to meet working capital
needs; the initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development
efforts; our ability to advance our product candidates into clinical
trials or to successfully complete our preclinical studies or clinical
trials; our receipt of regulatory approvals for our product candidates,
and the timing of other regulatory filings and approvals; the clinical
development, commercialization and market acceptance of our product
candidates; our ability to establish and maintain strategic partnerships
and other corporate collaborations; the implementation of our business
model and strategic plans for our business and product candidates; the
scope of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and our
ability to operate our business without infringing the intellectual
property rights of others; competitive companies, technologies and our
industry; statements as to the impact of the political and security
situation in Israel on our business; and risks and other risk factors
detailed in Can-Fite’s filings with the SEC and in its periodic filings
with the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced by
economic and other factors beyond its control. Can-Fite does not
undertake any obligation to publicly update these forward-looking
statements, whether as a result of new information, future events or
otherwise.

Contacts

Can-Fite BioPharma
Motti Farbstein
[email protected]
+972-3-9241114